Risk assessment and management of post-transplant diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 65, Issue 10, 2016, Pages 1559-1569

  Han, Eugene ^a,b   Kim, Myoung Soo ^c   Kim, Yu Seun ^c   Kang, Eun Seok ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Severance Hospital Diabetes Center   (United States)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Diabetes mellitus; Management; Organ transplantation; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; MAGNESIUM; MEGLITINIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

AGE; DIABETES MELLITUS; GENETIC BACKGROUND; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE; OBESITY; ORGAN TRANSPLANTATION; PATHOGENESIS; POST TRANSPLANT DIABETES MELLITUS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; ADVERSE EFFECTS; POSTOPERATIVE COMPLICATIONS;

DIABETES MELLITUS; HUMANS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS;

EID: 84981214786     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.07.011     Document Type: Review

References (129)

1. [1] Rana, A, Gruessner, A, Agopian, VG, Khalpey, Z, Riaz, IB, Kaplan, B, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg 150:3 (2015), 252–259.
2. [2] Bloom, RD, Crutchlow, MF, New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nnephrol 3:Suppl. 2 (2008), S38–S48.
3. [3] Kobashigawa, JA, Kasiske, BL, Hyperlipidemia in solid organ transplantation. Transplantation 63:3 (1997), 331–338.
4. [4] Friedman, AN, Miskulin, DC, Rosenberg, IH, Levey, AS, Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 41:2 (2003), 480–487.
5. [5] Laryea, M, Watt, KD, Molinari, M, Walsh, MJ, McAlister, VC, Marotta, PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 13:8 (2007), 1109–1114.
6. [6] Johnston, SD, Morris, JK, Cramb, R, Gunson, BK, Neuberger, J, Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73:6 (2002), 901–906.
7. [7] Diaz, JM, Gich, I, Bonfill, X, Sola, R, Guirado, L, Facundo, C, et al. Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival. Transplant Proc 41:6 (2009), 2151–2155.
8. [8] Starzl, TE, Marchioro, TL, Rifkind, D, Holmes, JH, Rowlands, DT Jr., Waddell, WR, Factors in successful renal transplantation. Surgery 56 (1964), 296–318.
9. [9] Sharif, A, Hecking, M, de Vries, AP, Porrini, E, Hornum, M, Rasoul-Rockenschaub, S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 14:9 (2014), 1992–2000.
10. [10] Ducloux, D, Kazory, A, Chalopin, JM, Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 79:4 (2005), 438–443.
11. [11] Rodrigo, E, Fernandez-Fresnedo, G, Valero, R, Ruiz, JC, Pinera, C, Palomar, R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nnephrol 17:12 Suppl. 3 (2006), S291–S295.
12. [12] Fernandez-Fresnedo, G, Escallada, R, de Francisco, ALM, Rodrigo, E, Zubimendi, JA, Ruiz, JC, et al. Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc, 35(2), 2003, 700.
13. [13] Wauters, RP, Cosio, FG, Suarez Fernandez, ML, Kudva, Y, Shah, P, Torres, VE, Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation 94:4 (2012), 377–382.
14. [14] Tsai, JP, Lian, JD, Wu, SW, Hung, TW, Tsai, HC, Chang, HR, Long-term impact of Pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg 35:12 (2011), 2818–2825.
15. [15] Hjelmesaeth, J, Hartmann, A, Leivestad, T, Holdaas, H, Sagedal, S, Olstad, M, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69:3 (2006), 588–595.
16. [16] American Diabetes Association, 4. Prevention or delay of type 2 diabetes. Diabetes Care 39:Suppl. 1 (2016), S36–S38.
17. [17] Hjelmesaeth, J, Hagen, M, Hartmann, A, Midtvedt, K, Egeland, T, Jenssen, T, The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 16:6 (2002), 389–396.
18. [18] Hjelmesaeth, J, Midtvedt, K, Jenssen, T, Hartmann, A, Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care 24:12 (2001), 2121–2126.
19. [19] Vincenti, F, Friman, S, Scheuermann, E, Rostaing, L, Jenssen, T, Campistol, JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7:6 (2007), 1506–1514.
20. [20] Hornum, M, Jorgensen, KA, Hansen, JM, Nielsen, FT, Christensen, KB, Mathiesen, ER, et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin J Am Soc Nephrol 5:4 (2010), 709–716.
21. [21] Boudreaux, JP, Mchugh, L, Canafax, DM, Ascher, N, Sutherland, DER, Payne, W, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal-allograft recipients. Transplantation 44:3 (1987), 376–381.
22. [22] Kasiske, BL, Snyder, JJ, Gilbertson, D, Matas, AJ, Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3:2 (2003), 178–185.
23. [23] Hur, KY, Kim, MS, Kim, YS, Kang, ES, Nam, JH, Kim, SH, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 30:3 (2007), 609–615.
24. [24] Sumrani, NB, Delaney, V, Ding, ZK, Davis, R, Daskalakis, P, Friedman, EA, et al. Diabetes mellitus after renal transplantation in the cyclosporine era–an analysis of risk factors. Transplantation 51:2 (1991), 343–347.
25. [25] Chakkera, HA, Hanson, RL, Raza, SM, DiStefano, JK, Millis, MP, Heilman, RL, et al. Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc 41:10 (2009), 4172–4177.
26. [26] Sumrani, N, Delaney, V, Ding, Z, Davis, R, Daskalakis, P, Friedman, EA, et al. Posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplant Proc 23 (1991), 1249–1250.
27. [27] Peracha, J, Nath, J, Ready, A, Tahir, S, Parekh, K, Hodson, J, et al. Risk of post-transplantation diabetes mellitus is greater in south Asian versus Caucasian kidney allograft recipients. Transpl Int 29:6 (2016), 727–739.
28. [28] Lee, HC, Post-renal transplant diabetes mellitus in korean subjects: superimposition of transplant-related immunosuppressant factors on genetic and type 2 diabetic risk factors. Diabetes Metab J 36:3 (2012), 199–206.
29. [29] Kang, ES, Kim, MS, Kim, CH, Nam, CM, Han, SJ, Hur, KY, et al. Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea. Transplantation 88:5 (2009), 693–698.
30. [30] Kang, ES, Kim, MS, Kim, YS, Hur, KY, Han, SJ, Nam, CM, et al. A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care 31:1 (2008), 63–68.
31. [31] Kang, ES, Kim, MS, Kim, YS, Kim, CH, Han, SJ, Chun, SW, et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 57:4 (2008), 1043–1047.
32. [32] Lee, YH, Kang, ES, Kim, SH, Han, SJ, Kim, CH, Kim, HJ, et al. Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. J Hum Genet 53:11–12 (2008), 991–998.
33. [33] Kang, ES, Magkos, F, Kim, BS, Zhai, R, Su, L, Kim, YS, et al. Variants of the adiponectin and adiponectin receptor-1 genes and posttransplantation diabetes mellitus in renal allograft recipients. J Clin Endocrinol Metab 97:1 (2012), E129–E135.
34. [34] Kurzawski, M, Dziewanowski, K, Kedzierska, K, Gornik, W, Banas, A, Drozdzik, M, Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacogenomics J 10:2 (2010), 120–125.
35. [35] Yang, J, Hutchinson, II, Shah, T, Min, DI, Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 91:10 (2011), 1114–1119.
36. [36] Lee, S, Moon, JY, Lee, SH, Ihm, CG, Lee, TW, Kim, SK, et al. Angiotensinogen polymorphisms and post-transplantation diabetes mellitus in Korean renal transplant subjects. Kidney Blood Press Res 37:2–3 (2013), 95–102.
37. [37] Chen, Y, Sampaio, MS, Yang, JW, Min, D, Hutchinson, IV, Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 93:3 (2012), 325–330.
38. [38] Kim, I, Kang, ES, Yim, YS, Ko, SJ, Jeong, SH, Rim, JH, et al. A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion. Pharmacogenomics J 11:3 (2011), 191–198.
39. [39] Bamoulid, J, Courivaud, C, Deschamps, M, Mercier, P, Ferrand, C, Penfornis, A, et al. IL-6 promoter polymorphism − 174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 17:8 (2006), 2333–2340.
40. [40] Parikh, CR, Klem, P, Wong, C, Yalavarthy, R, Chan, L, Obesity as an independent predictor of posttransplant diabetes mellitus. Transplant Proc 35:8 (2003), 2922–2926.
41. [41] Johnson, CP, Gallagher-Lepak, S, Zhu, YR, Porth, C, Kelber, S, Roza, AM, et al. Factors influencing weight gain after renal transplantation. Transplantation 56:4 (1993), 822–827.
42. [42] El-Agroudy, AE, Wafa, EW, Gheith, OE, El-Dein, ABS, Ghoneim, MA, Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation 77:9 (2004), 1381–1385.
43. [43] Porrini, E, Delgado, P, Bigo, C, Alvarez, A, Cobo, M, Checa, MD, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 48:1 (2006), 134–142.
44. [44] Laaksonen, DE, Lakka, HM, Salonen, JT, Niskanen, LK, Rauramaa, R, Lakka, TA, Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care 25:9 (2002), 1612–1618.
45. [45] Lutsey, PL, Steffen, LM, Stevens, J, Dietary intake and the development of the metabolic syndrome: the atherosclerosis risk in communities study. Circulation 117:6 (2008), 754–761.
46. [46] Gursoy, M, Guvener, N, Koksal, R, Karavelioglu, D, Baysal, C, Ozdemir, N, et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 32:3 (2000), 561–562.
47. [47] Bloom, RD, Rao, V, Weng, F, Grossman, RA, Cohen, D, Mange, KC, Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13:5 (2002), 1374–1380.
48. [48] Fabrizi, F, Martin, P, Dixit, V, Bunnapradist, S, Kanwal, F, Dulai, G, Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 5:10 (2005), 2433–2440.
49. [49] Saliba, F, Lakehal, M, Pageaux, GP, Roche, B, Vanlemmens, C, Duvoux, C, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 13:1 (2007), 136–144.
50. [50] Eslam, M, Khattab, MA, Harrison, SA, Insulin resistance and hepatitis C: an evolving story. Gut 60:8 (2011), 1139–1151.
51. [51] Simo, R, Lecube, A, Genesca, J, Esteban, JI, Hernandez, C, Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 29:11 (2006), 2462–2466.
52. [52] Ekberg, H, Tedesco-Silva, H, Demirbas, A, Vitko, S, Nashan, B, Gurkan, A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:25 (2007), 2562–2575.
53. [53] Woodward, RS, Schnitzler, MA, Baty, J, Lowell, JA, Lopez-Rocafort, L, Haider, S, et al. Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transplant 3:5 (2003), 590–598.
54. [54] Hakeam, HA, Al-Jedai, AH, Raza, SM, Hamawi, K, Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant 13:2 (2008), 46–53.
55. [55] Johnston, O, Rose, CL, Webster, AC, Gill, JS, Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19:7 (2008), 1411–1418.
56. [56] Ozbay, LA, Smidt, K, Mortensen, DM, Carstens, J, Jorgensen, KA, Rungby, J, Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Brit J Pharmacol 162:1 (2011), 136–146.
57. [57] Pereira, MJ, Palming, J, Rizell, M, Aureliano, M, Carvalho, E, Svensson, MK, et al. Cyclosporine a and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J Clin Endocrinol Metab 99:10 (2014), E1885–E1894.
58. [58] Rathi, M, Rajkumar, V, Rao, N, Sharma, A, Kumar, S, Ramachandran, R, et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. Transplant Proc 47:4 (2015), 1158–1161.
59. [59] Webster, A, Woodroffe, RC, Taylor, RS, Chapman, JR, Craig, JC, Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev, 4, 2005, CD003961.
60. [60] Vicenti, F, Jensik, SC, Filo, RS, Miller, J, Pirsch, J, A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73:5 (2002), 775–782.
61. [61] Prokai, A, Fekete, A, Pasti, K, Rusai, K, Banki, NF, Reusz, G, et al. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus. Pediatr Diabetes 13:1 (2012), 81–91.
62. [62] Pereira, MJ, Palming, J, Rizell, M, Aureliano, M, Carvalho, E, Svensson, MK, et al. mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes. Mol Cell Endocrinol 355:1 (2012), 96–105.
63. [63] Midtvedt, K, Hjelmesaeth, J, Hartmann, A, Lund, K, Paulsen, D, Egeland, T, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 15:12 (2004), 3233–3239.
64. [64] Woodle, ES, First, MR, Pirsch, J, Shihab, F, Gaber, AO, Van Veldhuisen, P, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 Day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 248:4 (2008), 564–577.
65. [65] Pirsch, JD, Henning, AK, First, MR, Fitzsimmons, W, Gaber, AO, Reisfield, R, et al. New-onset diabetes after transplantation: results from a double-blind early corticosteroid withdrawal trial. Am J Transplant 15:7 (2015), 1982–1990.
66. [66] Vincenti, F, Schena, FP, Paraskevas, S, Hauser, IA, Walker, RG, Grinyo, J, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 8:2 (2008), 307–316.
67. [67] Knight, SR, Morris, PJ, Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 89:1 (2010), 1–14.
68. [68] Gonyea, JE, Anderson, CF, Weight change and serum lipoproteins in recipients of renal allografts. Mayo Clin Proc 67:7 (1992), 653–657.
69. [69] Wissing, KM, Unger, P, Ghisdal, L, Broeders, N, Berkenboom, G, Carpentier, Y, et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 82:6 (2006), 771–778.
70. [70] McCune, TR, Thacker, LR II, Peters, TG, Mulloy, L, Rohr, MS, Adams, PA, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a southeastern organ procurement foundation multicenter clinical study. Transplantation 65:1 (1998), 87–92.
71. [71] Ligtenberg, G, Hene, RJ, Blankestijn, PJ, Koomans, HA, Cardiovascular risk factors in renal transplant patients: cyclosporin a versus tacrolimus. J Am Soc Nephrol 12:2 (2001), 368–373.
72. [72] Pereira, MJ, Palming, J, Rizell, M, Aureliano, M, Carvalho, E, Svensson, MK, et al. The immunosuppressive agents rapamycin, cyclosporin a and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue. Mol Cell Endocrinol 365:2 (2013), 260–269.
73. [73] Riella, LV, Gabardi, S, Chandraker, A, Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant 12:8 (2012), 1975–1982.
74. [74] Kasiske, B, Cosio, FG, Beto, J, Bolton, K, Chavers, BM, Grimm, R Jr., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the managing dyslipidemias in chronic kidney disease work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4:Suppl. 7 (2004), 13–53.
75. [75] Ridker, PM, Pradhan, A, MacFadyen, JG, Libby, P, Glynn, RJ, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380:9841 (2012), 565–571.
76. [76] Ridker, PM, Danielson, E, Fonseca, FA, Genest, J, Gotto, AM Jr., Kastelein, JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:21 (2008), 2195–2207.
77. [77] Parhofer, KG, Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J 39:5 (2015), 353–362.
78. [78] Preiss, D, Seshasai, SR, Welsh, P, Murphy, SA, Ho, JE, Waters, DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:24 (2011), 2556–2564.
79. [79] Choe, EY, Wang, HJ, Kwon, O, Cho, Y, Huh, KH, Kim, MS, et al. HMG CoA Reductase inhibitor treatment induces Dysglycemia in renal allograft recipients. Transplantation 97:4 (2014), 419–425.
80. [80] Cho, Y, Lee, MJ, Choe, EY, Jung, CH, Joo, DJ, Kim, MS, et al. Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels. Liver Transpl 20:5 (2014), 557–563.
81. [81] Tosiello, L, Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 156:11 (1996), 1143–1148.
82. [82] Van Laecke, S, Van Biesen, W, Verbeke, F, De Bacquer, D, Peeters, P, Vanholder, R, Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 9:9 (2009), 2140–2149.
83. [83] Huang, JW, Famure, O, Li, Y, Kim, SJ, Hypomagnesemia and the risk of new-onset diabetes mellitus after kidney transplantation. J Am Soc Nephrol 27:6 (2016), 1793–1800.
84. [84] Nijenhuis, T, Hoenderop, JG, Bindels, RJ, Downregulation of Ca(2 +) and Mg(2 +) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 15:3 (2004), 549–557.
85. [85] Mazzola, BL, Vannini, SD, Truttmann, AC, von Vigier, RO, Wermuth, B, Ferrari, P, et al. Long-term calcineurin inhibition and magnesium balance after renal transplantation. Transpl Int 16:2 (2003), 76–81.
86. [86] Van Laecke, S, Nagler, EV, Taes, Y, Van Biesen, W, Peeters, P, Vanholder, R, The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int 27:9 (2014), 895–902.
87. [87] Jenssen, T, Hartmann, A, Prevention and management of transplant-associated diabetes. Expert Opin Pharmacother 12:17 (2011), 2641–2655.
88. [88] Baid, S, Cosimi, AB, Farrell, ML, Schoenfeld, DA, Feng, S, Chung, RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 72:6 (2001), 1066–1072.
89. [89] Cho, YM, Park, KS, Jung, HS, Jeon, HJ, Ahn, C, Ha, J, et al. High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria. Diabetes Care 26:4 (2003), 1123–1128.
90. [90] Jenssen, T, Hartmann, A, Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol 11:8 (2015), 465–477.
91. [91] Lane, JT, Dagogo-Jack, S, Approach to the patient with new-onset diabetes after transplant (NODAT). J Clin Endocrinol Metab 96:11 (2011), 3289–3297.
92. [92] Iida, S, Ishida, H, Tokumoto, T, Omoto, K, Shirakawa, H, Shimizu, T, et al. New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT. Int Urol Nephrol 42:4 (2010), 935–945.
93. [93] Knowler, WC, Barrett-Connor, E, Fowler, SE, Hamman, RF, Lachin, JM, Walker, EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:6 (2002), 393–403.
94. [94] Diabetes Prevention Program Research G, Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol 3:11 (2015), 866–875.
95. [95] Werzowa, J, Hecking, M, Haidinger, M, Lechner, F, Doller, D, Pacini, G, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 95:3 (2013), 456–462.
96. [96] Kamar, N, Toupance, O, Buchler, M, Sandres-Saune, K, Izopet, J, Durand, D, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14:8 (2003), 2092–2098.
97. [97] Cosio, FG, Kudva, Y, van der Velde, M, Larson, TS, Textor, SC, Griffin, MD, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67:6 (2005), 2415–2421.
98. [98] Shivaswamy, V, Boerner, B, Larsen, J, Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev 37:1 (2016), 37–61.
99. [99] Sharif, A, Moore, R, Baboolal, K, Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 85:3 (2008), 353–358.
100. [100] Neuvonen, PJ, Niemi, M, Backman, JT, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:6 (2006), 565–581.
101. [101] American Diabetes Association, (7) approaches to glycemic treatment. Diabetes Care 39:Suppl. 1 (2016), S52–S59.
102. [102] Kim, MJ, Han, JY, Shin, JY, Kim, SI, Lee, JM, Hong, S, et al. Metformin-associated lactic acidosis: predisposing factors and outcome. Endcorinol Metab (Seoul) 30:1 (2015), 78–83.
103. [103] Lipska, KJ, Bailey, CJ, Inzucchi, SE, Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34:6 (2011), 1431–1437.
104. [104] Harrower, AD, Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31:2 (1996), 111–119.
105. [105] Kahn, CR, Chen, L, Cohen, SE, Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106:11 (2000), 1305–1307.
106. [106] Han, E, Jang, SY, Kim, G, Lee, YH, Choe, EY, Nam, CM, et al. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine, 95, 2016, e2786.
107. [107] Voytovich, MH, Simonsen, C, Jenssen, T, Hjelmesaeth, J, Asberg, A, Hartmann, A, Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 20:2 (2005), 413–418.
108. [108] Nissen, SE, Wolski, K, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:24 (2007), 2457–2471.
109. [109] Drucker, DJ, The biology of incretin hormones. Cell Metab 3:3 (2006), 153–165.
110. [110] Halden, TA, Egeland, EJ, Asberg, A, Hartmann, A, Midtvedt, K, Khiabani, HZ, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes. Diabetes Care 39:4 (2016), 617–624.
111. [111] Vilsboll, T, Holst, JJ, Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:3 (2004), 357–366.
112. [112] Cho, YM, Wideman, RD, Kieffer, TJ, Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) 28 (2013), 262–274.
113. [113] Mita, T, Katakami, N, Yoshii, H, Onuma, T, Kaneto, H, Osonoi, T, et al. Alogliptin, a Dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of Alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care 39:1 (2016), 139–148.
114. [114] Green, JB, Bethel, MA, Armstrong, PW, Buse, JB, Engel, SS, Garg, J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:3 (2015), 232–242.
115. [115] Strom Halden, TA, Asberg, A, Vik, K, Hartmann, A, Jenssen, T, Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 29:4 (2014), 926–933.
116. [116] Lane, JT, Odegaard, DE, Haire, CE, Collier, DS, Wrenshall, LE, Stevens, RB, Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 92:10 (2011), e56–e57.
117. [117] Haidinger, M, Werzowa, J, Hecking, M, Antlanger, M, Stemer, G, Pleiner, J, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation–a randomized, double-blind, placebo-controlled trial. Am J Transplant 14:1 (2014), 115–123.
118. [118] Yun, Y, Kang, ES, Management of Diabetes in organ transplant patients. J Korean Diabetes 15 (2014), 134–141.
119. [119] Jung, GS, Jeon, JH, Choe, MS, Kim, SW, Lee, IK, Kim, MK, et al. Renoprotective effect of gemigliptin, a Dipeptidyl peptidase-4 inhibitor, in Streptozotocin-induced type 1 diabetic mice. Diabetes Metab J 40:3 (2016), 211–221.
120. [120] Hediger, MA, Rhoads, DB, Molecular physiology of sodium-glucose cotransporters. Physiol Rev 74:4 (1994), 993–1026.
121. [121] Vallon, V, Gerasimova, M, Rose, MA, Masuda, T, Satriano, J, Mayoux, E, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306:2 (2014), F194–F204.
122. [122] Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:22 (2015), 2117–2128.
123. [123] Taylor, SI, Blau, JE, Rother, KI, SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100:8 (2015), 2849–2852.
124. [124] Nauck, MA, Del Prato, S, Duran-Garcia, S, Rohwedder, K, Langkilde, AM, Sugg, J, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 16:11 (2014), 1111–1120.
125. [125] American Diabetes Association, 13. Diabetes Care in the Hospital. Diabetes Care 39:Suppl. 1 (2016), S99–104.
126. [126] Hecking, M, Haidinger, M, Doller, D, Werzowa, J, Tura, A, Zhang, J, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 23:4 (2012), 739–749.
127. [127] Asberg, A, Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63:4 (2003), 367–378.
128. [128] Islam, SI, Masuda, QN, Bolaji, OO, Shaheen, FM, Sheikh, IA, Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients. Ther Drug Monit 18 (1996), 624–626.
129. [129] Bae, J, Lee, MJ, Choe, EY, Jung, CH, Wang, HJ, Kim, MS, et al. Effects of Dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study. Endocrinol Metab (Seoul) 31:1 (2016), 161–167.